News Summary
Regeneron Pharmaceuticals has announced its acquisition of key assets of 23andMe for $256 million. This deal aims to merge Regeneron’s pharmaceutical expertise with 23andMe’s extensive DNA database, enhancing genetic research. The acquisition includes ownership of 23andMe’s Personal Genome Service and Research Services, while ensuring the company continues to operate as a subsidiary. The agreement is subject to bankruptcy court and regulatory approvals and will not include 23andMe’s telehealth platform. Regeneron’s commitment to consumer data privacy will be a priority throughout the process.
Regeneron Pharmaceuticals Acquires 23andMe for $256 Million
New York City – Regeneron Pharmaceuticals has announced plans to acquire key assets of 23andMe for $256 million, pending approval from bankruptcy court and regulatory authorities. This acquisition is expected to significantly impact the biotechnology sector by merging Regeneron’s pharmaceutical expertise with 23andMe’s vast consumer DNA database, enhancing genetics-driven research and drug development efforts.
Details of the Acquisition
The deal grants Regeneron ownership of 23andMe’s Personal Genome Service, Total Health, and Research Services divisions, along with an extensive biobank of genetic data. These assets align with Regeneron’s goal of targeting serious diseases, such as cancer and rare genetic disorders, through advanced research methodologies.
Despite the acquisition, 23andMe will continue to operate as a wholly owned subsidiary, maintaining its consumer DNA testing services. Regeneron has committed to respecting 23andMe’s existing privacy policies, ensuring consumer data protection. All genetic data utilized by Regeneron will be de-identified, consented, and compliant with applicable laws and ethical standards.
Impact on Employment and Services
Regeneron will retain all employees from the acquired business units of 23andMe, ensuring continuity in operations. However, the acquisition will not include 23andMe’s telehealth platform, Lemonaid Health, which is set to be discontinued as part of the restructuring plan.
Expected Timeline and Regulatory Approval
The anticipated closure of the deal is slated for the third quarter of 2025, subject to necessary regulatory and court approvals. A court-appointed Consumer Privacy Ombudsman will be responsible for overseeing data protection measures throughout the acquisition process.
Background on 23andMe
23andMe, which had once reached a valuation of approximately $6 billion, filed for Chapter 11 bankruptcy protection in March due to ongoing struggles with recurring revenue and privacy concerns. This decline was exacerbated by a significant data breach in 2023, which exposed the genetic information of nearly 7 million customers. The breach resulted in increased scrutiny regarding the company’s data handling practices.
Prior to its bankruptcy filing, 23andMe faced challenges in generating profits, despite initial public interest and investment in its services. The shift towards personalized medicine and genetic health insights has raised public awareness, making the company’s assets particularly appealing to firms like Regeneron.
In light of the acquisition, Regeneron has reiterated its commitment to not utilizing any personal data in ways that would violate prior agreements made by 23andMe, emphasizing the importance of consumer privacy and choice in managing genetic data.
Future of Personalized Medicine
The deal reflects a growing trend in the biotechnology field, as companies seek to leverage personalized medicine, ancestry research, and insights into genetic health risks. As these developments unfold, industry stakeholders are closely monitoring how this acquisition will influence both companies and the larger landscape of genetic research and pharmaceutical innovation.
Overall, Regeneron’s acquisition of 23andMe marks a significant chapter in the interplay between genetics and pharmaceuticals, offering potential advancements in medical treatments and ongoing research initiatives aimed at understanding complex diseases.
Deeper Dive: News & Info About This Topic
HERE Resources
Regeneron Acquires 23andMe for $256 Million
Additional Resources
- The New York Times
- Wikipedia: 23andMe
- CNBC
- Google Search: Regeneron 23andMe
- The Wall Street Journal
- Encyclopedia Britannica: Genetic Testing
- Reuters
- Google News: Biotechnology Mergers
- BBC News
- Google Scholar: Biotechnology Acquisition
Author: STAFF HERE NEW YORK WRITER
NEW YORK STAFF WRITER The NEW YORK STAFF WRITER represents the experienced team at HERENewYork.com, your go-to source for actionable local news and information in New York, the five boroughs, and beyond. Specializing in "news you can use," we cover essential topics like product reviews for personal and business needs, local business directories, politics, real estate trends, neighborhood insights, and state news affecting the area—with deep expertise drawn from years of dedicated reporting and strong community input, including local press releases and business updates. We deliver top reporting on high-value events such as New York Fashion Week, Macy's Thanksgiving Day Parade, and Tribeca Film Festival. Our coverage extends to key organizations like the Greater New York Chamber of Commerce and United Way of New York, plus leading businesses in finance and media that power the local economy such as JPMorgan Chase, Goldman Sachs, and Bloomberg. As part of the broader HERE network, including HEREBuffalo.com, we provide comprehensive, credible insights into New York's dynamic landscape.
